Tiffany Wallace, Ph.D.
Dr. Wallace is a Program Director in the Office of the Director at CRCHD and serves as a program navigator for health disparity research throughout NCI. In this role, she coordinates CRCHD’s programmatic efforts to strengthen NCI’s cancer health disparity research portfolio, encompassing basic, clinical, translational, and population-based research. Additional roles include co-managing a grant portfolio promoting basic cancer research in cancer health disparities, co-managing the phase-out of the Community Networks Program Centers (CNPCs) awards, co-managing Research Supplements to Promote Diversity in Health-Related Research, and representing CRCHD in the NCI’s Provocative Questions Initiative.
Prior to joining CRCHD, Dr. Wallace was an oncology scientist at Human Genome Sciences (HGS), a biopharmaceutical corporation acquired by GlaxoSmithKline in 2011. During her tenure at HGS she managed oncology research programs and conducted preclinical development of promising cancer therapeutic drugs and biologics.
Dr. Wallace received her Ph.D. in biomedical sciences from the University of Florida in Gainesville. She completed her postdoctoral training in the Laboratory of Human Carcinogenesis at NCI, where she conducted basic and translational research that provided novel insights on the role of biological factors as they contribute to cancer health disparities. Her research included identification of biomarkers of aggressive disease in prostate and breast cancers, with a focus on variations between different racial/ethnic groups.